Cargando…

Long-term effects of pegvisomant on comorbidities in patients with acromegaly: a retrospective single-center study

CONTEXT: The effect of pegvisomant on IGF1 levels in patients with acromegaly is well documented, but little is known of its long-term impact on comorbidity. AIM: The aim of this retrospective study was to evaluate the effects of long-term pegvisomant therapy on cardiorespiratory and metabolic comor...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuhn, Emmanuelle, Maione, Luigi, Bouchachi, Amir, Rozière, Myriam, Salenave, Sylvie, Brailly-Tabard, Sylvie, Young, Jacques, Kamenicky, Peter, Assayag, Patrick, Chanson, Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4592912/
https://www.ncbi.nlm.nih.gov/pubmed/26429918
http://dx.doi.org/10.1530/EJE-15-0500
_version_ 1782393251241656320
author Kuhn, Emmanuelle
Maione, Luigi
Bouchachi, Amir
Rozière, Myriam
Salenave, Sylvie
Brailly-Tabard, Sylvie
Young, Jacques
Kamenicky, Peter
Assayag, Patrick
Chanson, Philippe
author_facet Kuhn, Emmanuelle
Maione, Luigi
Bouchachi, Amir
Rozière, Myriam
Salenave, Sylvie
Brailly-Tabard, Sylvie
Young, Jacques
Kamenicky, Peter
Assayag, Patrick
Chanson, Philippe
author_sort Kuhn, Emmanuelle
collection PubMed
description CONTEXT: The effect of pegvisomant on IGF1 levels in patients with acromegaly is well documented, but little is known of its long-term impact on comorbidity. AIM: The aim of this retrospective study was to evaluate the effects of long-term pegvisomant therapy on cardiorespiratory and metabolic comorbidity in patients with acromegaly. PATIENTS AND METHODS: We analyzed the long-term (up to 10 years) effect of pegvisomant therapy given alone (n=19, 45%) or in addition to somatostatin analogues and/or cabergoline (n=23, 55%) on echocardiographic, polysomnographic and metabolic parameters in respectively 42, 12 and 26 patients with acromegaly followed in Bicêtre hospital. RESULTS: At the first cardiac evaluation, 20±16 months after pegvisomant introduction, IGF1 levels normalized in 29 (69%) of the 42 patients. The left ventricular ejection fraction (LVEF) improved significantly in patients whose basal LVEF was ≤60% and decreased in those whose LVEF was >70%. The left ventricular mass index (LVMi) decreased from 123±25 to 101±21 g/m(2) (P<0.05) in the 17 patients with a basal LVMi higher than the median (91 g/m(2)), while it remained stable in the other patients. Pegvisomant reduced the apnoea–hypopnea index and cured obstructive sleep apnea (OSA) in four of the eight patients concerned. Long-term follow-up of 22 patients showed continuing improvements in cardiac parameters. The BMI and LDL cholesterol level increased minimally during pegvisomant therapy, and other lipid parameters were not modified. CONCLUSIONS: Long-term pegvisomant therapy not only normalizes IGF1 in a large proportion of patients but also improves cardiac and respiratory comorbidity.
format Online
Article
Text
id pubmed-4592912
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Bioscientifica Ltd
record_format MEDLINE/PubMed
spelling pubmed-45929122015-11-01 Long-term effects of pegvisomant on comorbidities in patients with acromegaly: a retrospective single-center study Kuhn, Emmanuelle Maione, Luigi Bouchachi, Amir Rozière, Myriam Salenave, Sylvie Brailly-Tabard, Sylvie Young, Jacques Kamenicky, Peter Assayag, Patrick Chanson, Philippe Eur J Endocrinol Clinical Study CONTEXT: The effect of pegvisomant on IGF1 levels in patients with acromegaly is well documented, but little is known of its long-term impact on comorbidity. AIM: The aim of this retrospective study was to evaluate the effects of long-term pegvisomant therapy on cardiorespiratory and metabolic comorbidity in patients with acromegaly. PATIENTS AND METHODS: We analyzed the long-term (up to 10 years) effect of pegvisomant therapy given alone (n=19, 45%) or in addition to somatostatin analogues and/or cabergoline (n=23, 55%) on echocardiographic, polysomnographic and metabolic parameters in respectively 42, 12 and 26 patients with acromegaly followed in Bicêtre hospital. RESULTS: At the first cardiac evaluation, 20±16 months after pegvisomant introduction, IGF1 levels normalized in 29 (69%) of the 42 patients. The left ventricular ejection fraction (LVEF) improved significantly in patients whose basal LVEF was ≤60% and decreased in those whose LVEF was >70%. The left ventricular mass index (LVMi) decreased from 123±25 to 101±21 g/m(2) (P<0.05) in the 17 patients with a basal LVMi higher than the median (91 g/m(2)), while it remained stable in the other patients. Pegvisomant reduced the apnoea–hypopnea index and cured obstructive sleep apnea (OSA) in four of the eight patients concerned. Long-term follow-up of 22 patients showed continuing improvements in cardiac parameters. The BMI and LDL cholesterol level increased minimally during pegvisomant therapy, and other lipid parameters were not modified. CONCLUSIONS: Long-term pegvisomant therapy not only normalizes IGF1 in a large proportion of patients but also improves cardiac and respiratory comorbidity. Bioscientifica Ltd 2015-11 /pmc/articles/PMC4592912/ /pubmed/26429918 http://dx.doi.org/10.1530/EJE-15-0500 Text en © 2015 The authors http://creativecommons.org/licenses/by/3.0/deed.en_GB This work is licensed under a Creative Commons Attribution 3.0 Unported License (http://creativecommons.org/licenses/by/3.0/deed.en_GB)
spellingShingle Clinical Study
Kuhn, Emmanuelle
Maione, Luigi
Bouchachi, Amir
Rozière, Myriam
Salenave, Sylvie
Brailly-Tabard, Sylvie
Young, Jacques
Kamenicky, Peter
Assayag, Patrick
Chanson, Philippe
Long-term effects of pegvisomant on comorbidities in patients with acromegaly: a retrospective single-center study
title Long-term effects of pegvisomant on comorbidities in patients with acromegaly: a retrospective single-center study
title_full Long-term effects of pegvisomant on comorbidities in patients with acromegaly: a retrospective single-center study
title_fullStr Long-term effects of pegvisomant on comorbidities in patients with acromegaly: a retrospective single-center study
title_full_unstemmed Long-term effects of pegvisomant on comorbidities in patients with acromegaly: a retrospective single-center study
title_short Long-term effects of pegvisomant on comorbidities in patients with acromegaly: a retrospective single-center study
title_sort long-term effects of pegvisomant on comorbidities in patients with acromegaly: a retrospective single-center study
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4592912/
https://www.ncbi.nlm.nih.gov/pubmed/26429918
http://dx.doi.org/10.1530/EJE-15-0500
work_keys_str_mv AT kuhnemmanuelle longtermeffectsofpegvisomantoncomorbiditiesinpatientswithacromegalyaretrospectivesinglecenterstudy
AT maioneluigi longtermeffectsofpegvisomantoncomorbiditiesinpatientswithacromegalyaretrospectivesinglecenterstudy
AT bouchachiamir longtermeffectsofpegvisomantoncomorbiditiesinpatientswithacromegalyaretrospectivesinglecenterstudy
AT rozieremyriam longtermeffectsofpegvisomantoncomorbiditiesinpatientswithacromegalyaretrospectivesinglecenterstudy
AT salenavesylvie longtermeffectsofpegvisomantoncomorbiditiesinpatientswithacromegalyaretrospectivesinglecenterstudy
AT braillytabardsylvie longtermeffectsofpegvisomantoncomorbiditiesinpatientswithacromegalyaretrospectivesinglecenterstudy
AT youngjacques longtermeffectsofpegvisomantoncomorbiditiesinpatientswithacromegalyaretrospectivesinglecenterstudy
AT kamenickypeter longtermeffectsofpegvisomantoncomorbiditiesinpatientswithacromegalyaretrospectivesinglecenterstudy
AT assayagpatrick longtermeffectsofpegvisomantoncomorbiditiesinpatientswithacromegalyaretrospectivesinglecenterstudy
AT chansonphilippe longtermeffectsofpegvisomantoncomorbiditiesinpatientswithacromegalyaretrospectivesinglecenterstudy